TY - JOUR
KW - Humans
KW - *Bronchodilator Agents
KW - Retrospective Studies
KW - Financial Stress
KW - Drug Therapy, Combination
KW - Adrenergic beta-2 Receptor Agonists/therapeutic use
KW - Muscarinic Antagonists/therapeutic use
KW - Administration, Inhalation
AU - A. Czira
AU - V. Banks
AU - G. Requena
AU - R. Wood
AU - T. Tritton
AU - R. Wild
AU - C. Compton
AU - A. Ismaila
AD - Value Evidence and Outcomes, Epidemiology, GSK, R&D Global Medical, Brentford, Middlesex, UK.
Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Value Evidence and Outcomes, Epidemiology, GSK, R&D Global Medical, Brentford, Middlesex, UK gema.x.requena@gsk.com.
Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
AN - 38326272
BT - BMJ Open
C2 - PMC10860111
DO - 10.1136/bmjopen-2023-072361
DP - NLM
ET - 2024/02/08
LA - eng
M1 - 2
N1 - 2044-6055
Czira, Alexandrosz
Orcid: 0000-0002-3395-6186
Banks, Victoria
Orcid: 0000-0002-0087-7641
Requena, Gema
Orcid: 0000-0002-1889-6656
Wood, Robert
Orcid: 0000-0002-6977-435x
Tritton, Theo
Wild, Rosie
Orcid: 0000-0002-9963-6441
Compton, Chris
Orcid: 0000-0002-7564-5343
Ismaila, Afisi
Orcid: 0000-0002-2876-8308
Journal Article
Research Support, Non-U.S. Gov't
England
BMJ Open. 2024 Feb 7;14(2):e072361. doi: 10.1136/bmjopen-2023-072361.
PY - 2024
SN - 2044-6055
EP - e072361
T2 - BMJ Open
TI - Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B(2)-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study
VL - 14
ER -